Müllerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer

Carvalho, Filomena Marino; Carvalho, Jesus Paula; Motta, Eduardo Vieira da; Souen, Jorge Saad

doi:10.1590/s0041-87812000000100004

Cited by 15 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10] we also think that hormone receptors might play role in prognosis and be of significant clinical importance. Furthermore, some researchers had taken notice of the MASO cases occurring after tamoxifen therapy, suggesting a hormonal relationship [11]. Interestingly, endometrial curettage material of our case disclosed endometrial polyp with a hypercellular stroma, supporting this statement.…”

Section: Discussionsupporting

confidence: 80%

Müllerian Adenosarcoma with Sarcomatous Overgrowth of the Cervix

Çomunoğlu¹,

Comunoglu²,

Başsüllü³

et al. 2007

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

Müllerian adenosarcoma (MS) is a rare neoplasm of uterine cervix composed of benign epithelial and malignant stromal components. An aggressive variant of adenosarcoma, müllerian adenosarcoma with sarcomatous overgrowth (MASO) is extremely rare. The difference between MS and MASO is the pure high grade sarcoma features in MASO. In this report we present a MASO case, derived from uterine cervix of a 60 year-old-female patient presenting as a cervical polypoid mass, to our knowledge the second case of the English literature. In spite of sarcomatous overgrowth, high mitotic activity and huge tumor size of 12,5 cms, it displayed no myometrial invasion, vascular invasion and heterologous elements. The patient has been clinically free of disease for 14 months of follow up after total abdominal hysterectomy and bilateral salpingo-oopherectomy. The difficulties in diagnosis and treatment of this entity will be evaluated in this report.

show abstract

Section: Discussionsupporting

confidence: 80%

Müllerian Adenosarcoma with Sarcomatous Overgrowth of the Cervix

Çomunoğlu¹,

Comunoglu²,

Başsüllü³

et al. 2007

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

show abstract

“…The molecular mechanisms behind the development of uterine neoplasm of different histologies under tamoxifen therapy remain unexplained and further studies are needed. The mechanism of this increased risk is thought to be the estrogen agonist activity of tamoxifen on the uterus, which is similar to the mechanism for increased incidence of uterine cancer in women who take unopposed estrogen as hormone replacement therapy (4,5).…”

Section: Discussionmentioning

confidence: 99%

Myxoid Leiomyosarcoma of the Uterus in a Patient Receiving Tamoxifen Therapy: A Case Report

Botsis

Koliopoulos²,

Kondi-Pafitis³

et al. 2006

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

In this paper, we present a case of myxoid leiomyosarcoma development in a patient receiving tamoxifen for 3 years because of breast cancer. The myxoid leiomyosarcoma should be included in the differential diagnosis of any uterine tumor with a predominantly myxomatous composition. A review of the literature indicates that tamoxifen may increase not only the risk for endometrial cancer but also for uterine sarcoma, suggesting vigilance for uterine cancer in women who are being treated with this drug.

show abstract

“…This rare tumor was first described in 1974 and accounts for only 8% of all uterine sarcomas [1]. It has been suggested that primary müllerian adenosarcoma of the uterus may be associated with tamoxifen therapy [2,3].…”

mentioning

confidence: 99%